MK0767 and Metformin Combination Study (0767-028)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00543738

Enrollment

114

Registered

2007-10-15

Start date

2003-06-30

Completion date

2003-12-31

Last updated

2015-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

A study to test the effects of MK0767 when added to Metformin in patients with inadequately controlled Type 2 Diabetes Mellitus. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Interventions

DRUGMK0767

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

21 Years to 78 Years

Healthy volunteers

Inclusion criteria

* All women of childbearing potential must have a negative urine pregnancy test prior to starting the study * Patients must be on a stable dose of metformin for at least 2 weeks prior to visit 2

Exclusion criteria

* Patients with a history of type 1 diabetes mellitus and/or history of ketoacidosis * Patients on estrogen replacement therapy regimen or SERM * Patients with history of, allergy to, intolerance or hypersensitivity to statins or fibric acid derivatives, including history of elevated muscle and liver function tests, jaundice, hepatoxicity, or myopathy associated with these treatments * Patient is on a weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks from starting the study * Have active liver or gall bladder disease * HIV positive

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026